Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis. (PubMed, JAMA Neurol) - Oct 26, 2026 - "Rituximab, comparator DMTs (natalizumab, dimethyl fumarate, fingolimod), or general population comparator...Results of this cohort study show that rituximab was associated with an increased risk of IBD compared with other modern MS therapies, after adjustment for differences in characteristics at therapy start. Clinicians and individuals with MS should consider IBD risk in treatment decisions and remain vigilant for gastrointestinal symptoms during anti-CD20 therapy."
Journal • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Multiple Sclerosis • Ulcerative Colitis
|
|
Anders Svenningsson; Charlotte Hedin; Jan Lycke; Ola Olén; Peter Alping; Sandra Kallin
|